Segment Information - Summary of Segment Activity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Segment Reporting Information [Line Items]
Net revenue	$ 3,565	$ 2,552	$ 11,691	$ 8,345
Sales and marketing costs	(726)	(779)	(2,369)	(2,688)
Stock- based compensation expense	(237)	(567)	(1,901)	(2,090)
Consolidated [Member]
Segment Reporting Information [Line Items]
Net revenue	3,565	2,552	11,691	8,345
Direct cost of services	(2,404)	(2,103)	(7,081)	(6,288)
Sales and marketing costs	(719)	(752)	(2,175)	(2,516)
Other operating expenses	(1,606)	(1,503)	(4,954)	(5,218)
Stock- based compensation expense	(237)	(567)	(1,901)	(2,090)
Segment profit (loss)	(1,401)	(2,373)	(4,420)	(7,767)
Operating Segments [Member] | Personalized Oncology Solutions [Member]
Segment Reporting Information [Line Items]
Net revenue	347	416	1,354	1,387
Direct cost of services	(320)	(479)	(1,165)	(1,634)
Sales and marketing costs	(128)	(183)	(397)	(716)
Other operating expenses	0	0	0	0
Stock- based compensation expense	0	0	0	0
Segment profit (loss)	(101)	(246)	(208)	(963)
Operating Segments [Member] | Translational Oncology Solutions [Member]
Segment Reporting Information [Line Items]
Net revenue	3,218	2,136	10,337	6,958
Direct cost of services	(2,084)	(1,624)	(5,916)	(4,654)
Sales and marketing costs	(591)	(569)	(1,778)	(1,800)
Other operating expenses	(953)	(950)	(3,043)	(2,755)
Stock- based compensation expense	0	0	0	0
Segment profit (loss)	(410)	(1,007)	(400)	(2,251)
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Net revenue	0	0	0	0
Direct cost of services	0	0	0	0
Sales and marketing costs	0	0	0	0
Other operating expenses	(653)	(553)	(1,911)	(2,463)
Stock- based compensation expense	(237)	(567)	(1,901)	(2,090)
Segment profit (loss)	$ (890)	$ (1,120)	$ (3,812)	$ (4,553)